Lutein + Zeaxanthin

Supported by AREDS2 context for AMD progression risk reduction when used as part of a specific formula in at-risk populations.

womens-healthlongevityimmune-support

Dosing model

FLATFixed dose (no body-weight scaling).

Min dose

10 mg

Max dose

20 mg

Rounding

1 mg

Buy this ingredient ← Back

Stacks containing Lutein + Zeaxanthin

Public community stacks that include this ingredient.

Explore all stacks →

No public stacks include this ingredient yet.

Evidence

2 records

AMD progression risk modification (AREDS2 context)

Adults at risk for advanced AMD • Large randomized clinical trial program

Moderate

NEI summaries describe AREDS2 testing lutein/zeaxanthin additions and related outcomes in AMD risk contexts.

Dose: 12 mg • Duration: Long-term (trial program)

Citation: NIH NEI – About AREDS/AREDS2 clinical trials

AMD progression to advanced AMD — primary RCT results

Adults aged 50–85 at risk for advanced AMD (n=4,203) • Randomized clinical trial (AREDS2)

Moderate

The AREDS2 primary report found lutein 10 mg + zeaxanthin 2 mg did not significantly reduce progression to advanced AMD vs placebo overall; however, secondary analyses showed lutein/zeaxanthin reduced risk in participants with the lowest dietary intake of these carotenoids. Long-term 10-year follow-up (AREDS2 Report 28) found HR 0.91 (95% CI 0.84–0.99) favoring lutein/zeaxanthin.

Dose: 10 mg • Duration: Median ~5 years

Citation: Age-Related Eye Disease Study 2 Research Group. Lutein + zeaxanthin and omega-3 fatty acids for age-related macular degeneration: the AREDS2 randomized clinical trial. JAMA. 2013;309(19):2005-2015.

Forms

Capsule

Often 10 mg lutein + 2 mg zeaxanthin in AREDS2-style formulas